Pregnancy, breast-feeding and drugs used in dentistry

Journal of the American Dental Association

Volumn 143, Issue 8, 2012, Pages 858-871

  Donaldson, Mark ^a,b,c,d   Goodchild, Jason H ^d,e  

^a KALISPELL REGIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MONTANA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d University of Pennsylvania ^*

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Fetotoxicity; Lactation; Medications; Pregnancy; Pregnancy complications; Risk assessment; Teratology

Indexed keywords

EID: 84865511209     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2012.0290     Document Type: Article

References (111)

1. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191(2):398-407.
2. Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, National Birth Defects Prevention Network. Important Information About Preventing Birth Defects. www.nbdpn.org/docs/Pamplet-BDprevention.pdf. Accessed June 8,2012.
3. Chambers CD, Braddock SR, Briggs GG, et al. Postmarketing surveillance for human teratogenicity: a model approach. Teratology 2001;64(5):252-261.
4. Irl C, Hasford J. Assessing the safety of drugs in pregnancy: the role of prospective cohort studies. Drug Saf 2000;22(3):169-177.
5. Martmez-Frfas ML. Postmarketing analysis of medicines: methodology and value of the Spanish case-control study and surveillance system in preventing birth defects. Drug Saf 2007;30(4):307-316.
6. Wilson JG. Present status of drugs as teratogens in man. Teratology 1973;7(1):3-15.
7. Michalowicz BS, DiAngelis AJ, Novak MJ, et al. Examining the safety of dental treatment in pregnant women. JADA 2008; 139(6): 685-695.
8. U.S. Food and Drug Administration. Drug safety and availability. www.fda.gov/Drugs/DrugSafety/default.htm. Accessed June 26, 2012.
9. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30(1):24-29, 46.
10. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006;38(2):90-96.
11. Simpson JL. Genetics in Obstetrics and Gynecology. New York City: Grune & Stratton; 1982:203-210.
12. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 9th ed. Philadelphia: Wolters Muwer/Lippincott Williams & Wilkins; 2011: xvii, 406-408, 497.
13. Boubred F, Vendemmia M, Garcia-Meric P, Buffat C, Millet V, Simeoni U. Effects of maternally administered drugs on the fetal and neonatal kidney. Drug Saf 2006;29(5):397-419.
14. Adverse Drug Reactions Advisory Committee. Premature closure of the fetal ductus arteriosus after maternal use of non-steroidal anti-inflammatory drugs. Med J Aust 1998;169(5):270-271.
15. Iusley NP, Hall S, Penfold P, Stacey TE. Diflusional permeability of the human placenta. Contrib Gynecol Obstet 1985;13:92-97.
16. Kraemer K. Placental transfer of drugs. Neonatal Netw 1997; 16(2):65-67.
17. Jankowitz J. Drugs in pregnancy. In: Gibbs RS, Danforth DN, eds. Danforth's Obstetrics and Gynecology. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:122-123.
18. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception anil pregnancy. Am J Gastroenterol 2009;104(1):228-233.
19. Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011;106(9):1594-1602.
20. U.S. Food and Drug Administration. Labeling requirements for over-the-counter drugs. 21 CFR Part 201.80. http:/www.accessdata.fda.gov/ scripts/cdrWcfdMs/cfCFR/CFRSearch.cfm?fr=201.80&utm-campaign= Google2&utm-source=fdaSearch&utm-medium=website&utm-term= 1979prgnancycategories&utm-content=3. Accessed June 26, 2012.
21. U.S. Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling (proposed rule). Fed Regist 2008;73(104): 30831-30868. 21 CFR Part 201. www.gpo.gov/fdsys/pkg/FR-2008-05-29/html/E8-11806.htm. Accessed June 8, 2012.
22. Centers for Disease Control and Prevention. Breastfeeding Among U.S. Children Born 2000-2008, CDC National Immunization Survey. www.cdc.gov/ breastfeeding/data/NIS-data/index.htm. Accessed June 8, 2012.
23. Hendrickson RG, McKeown NJ. Is maternal opioid use hazardous to breast-fed infants? (published online ahead of print Dec. 13, 2001). Clin Toxicol (Phila) 2012;50(1):1-14. doi:10.3109/15563650.2011.635147.
24. American Academy of Pediatrics. AAP issues policy statement on the transfer of drugs and other chemicals into human milk. Am Fam Physician 1994;49(6):1527-1529.
25. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk: clinical pharmacokinetic considerations. Clin Pharmacokinet 1988;14(4): 217-240.
26. Bowes WA Jr. The effect of medications on the lactating mother and her infant. Clin Obstet Gynecol 1980;23(4):1073-1080.
27. Wilson JT, Brown RD, Cherek DR, et al. Drug excretion in human breast milk: principles, pharmacokinetics and projected consequences. Clin Pharmacokinet 1980;5(1):1-66.
28. Banta-Wright SA. Minimizing infant exposure to and risks from medications while breastfeeding. J Perinat Neonatal Nurs 1997; 11(2):71-84.
29. Berglund F, Flodh H, Lundborg P, Prame B, Sannerstedt R. Drug use during pregnancy and breast-feeding: a classification system for drug information. Acta Obstet Gynecol Scand Suppl 1984; 126:1-55.
30. Friguls B, Joya X, Garcfa-Algar O, Pallas CR, Vail O, Pichini S. A comprehensive review of assay methods to determine drugs in breast milk and the safety of breastfeeding when taking drugs (published online ahead of print April 13,2010). Anal Bioanal Chem 2010;397(3):1157-1179.doi:10.1107/s00216-010-3681- 0.
31. Henderson E, Mackillop L. Prescribing in pregnancy and during breast feeding: using principles in clinical practice (published online ahead of print Jan. 27, 2011). Postgrad Med J 2011;87(1027): 349-354. doi:10.1136/pgmj.2010. 103606.
32. Rutherford JM. Drugs in breastfeeding. In: Rubin P, Ramsay M, eds. Prescribing in Pregnancy. 4th ed. Maiden, Mass.: BMJ Books, Blackwell Publishing; 2008:216-229.
33. Liporace J, Kao A, D'Abreu A. Concerns regarding lamotrigine and breast-feeding. Epilepsy Behav 2004;5(1):102-105.
34. Hale TW, Ilett KF. Drug Therapy and Breastfeeding: From Theory to Clinical Practice. New York City: Parthenon; 2002:25.
35. Lee KG. Lactation and drugs. Paediatr Child Health 2007; 17(2):68-71.
36. Spigset O, Hagg S. Analgesics and breast-feeding: safety considerations. Paediatr Drugs 2000;2(3):223-238.
37. Howie WO, McMullen PC. Breastfeeding problems following anesthetic administration. J Perinat Educ 2006;15(3):50-57.
38. Winter ME. Basic Clinical Pharmacokinetics. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010: 41.
39. Brambilla E, Felloni A, Gagliani M, Malerba A, Garcia-Godoy F, Strohmenger L. Caries prevention during pregnancy: results of a 30-month study. JADA 1998;129(7):871-877.
40. Gunay H, Dmoch-Bockhorn K, Gunay Y, Geurtsen W. Effect on caries experience of a long-term preventive program for mothers and children starting during pregnancy. Clin Oral Investig 1998;2(3): 137-142.
41. Leverett DH, Adair SM, Vaughan BW, Proskin HM, Moss ME. Randomized clinical trial of the effect of prenatal fluoride supplements in preventing dental caries. Caries Res 1997;31(3):174-179.
42. American Academy of Pediatric Dentistry. Guideline on fluoride therapy. Pediatr Dent 2007;29(7):111-114.
43. American Academy of Pediatric Dentistry Council on Clinical Affairs Committee on the Adolescent. Guideline on health care of the pregnant adolescent. Pediatr Dent 2008-2009;30(7 suppl):102-106.
44. Rosenberg M. Preparing for medical emergencies: the essential drugs and equipment for the dental office. JADA 2010;141(suppl 1): 14S-19S.
45. Burdan F, Belzek A. Current opinions on embryotoxic and teratogenic effects of ibuprofen (in Polish). Pol Merkur Lekarski 2001; 11(63):266-270.
46. Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJ. Maternal medications and environmental exposures as risk factors for gas-troschisis. Teratology 1996;54(2):84-92.
47. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62(6): 385-392.
48. Bonner JJ, Tyan ML. Backcross test demonstrates the linkage of glucocorticoid-induced cleft palate susceptibility to H-2. Teratology 1982;26(2):213-216.
49. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3): 776-789.
50. Kallen BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003;17(3): 255-261.
51. Cleves MA, Savell VH Jr, Raj S, et al. Maternal use of aceta- minophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects. Birth Defects Res A Clin Mol Teratol 2004;70(3):107-113.
52. Matheson I, Lunde PK, Notarianni L. Infant rash caused by paracetamol in breast milk? Pediatrics 1985;76(4):651-652.
53. Donaldson M, Goodchild JH. Appropriate analgesic prescribing for the general dentist. Gen Dent 2010;58(4):291-297.
54. Becker DE. Pain management, part 1: managing acute and postoperative dental pain. Anesth Prog 2010;57(2):67-78.
55. Madadi P, Moretti M, Djokanovic N, et al. Guidelines for maternal codeine use during breastfeeding. Can Fam Phys 2009;55( 11): 1077-1078.
56. Berlin CM, Paul IM, Vesell ES. Safety issues of maternal drug therapy during breastfeeding. Clin Pharmacol Ther 2009;85(1):20-22.
57. TVedwin CJ, Scully C, Bagan-Sebastian JV. Drug-induced disorders of teeth. J Dent Res 2005;84(7):596-602.
58. Lochary ME, Lockhart PB, Williams WT Jr. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J 1998;17(5):429-431.
59. Vibramycin (prescribing information). New York City: Pfizer, 2007.
60. Biaxin (prescribing information). North Chicago, 111.: Abbott Laboratories; 2011.
61. Zithromax (prescribing information). New York City: Pfizer; 2011.
62. Erythromycin base (prescribing information). Raleigh, N.C.: Arbor Pharmaceuticals; 2011.
63. Sorensen HT, Skriver MV, Pedersen L, Larsen H, Ebbesen F, Schonheyder HC. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scand J Infect Dis 2003;35(2): 104-106.
64. Stang H. Pyloric stenosis associated with erythromycin ingested through breastmilk. Minn Med 1986;69(11):669-670, 682.
65. Czeizel AE, Kazy Z, Puhd E. A population-based case-control teratological study of oral nystatin treatment during pregnancy. Scand J Infect Dis 2003;35(11-12):830-835.
66. das Neves J, Pinto E, leixeira B, et al. Local treatment of vulvovaginal candidosis: general and practical considerations. Drugs 2008;68(13):1787-1802.
67. Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev 2001;(4): CD000225.
68. Norgaard M, Pedersen L, Gislum M, et al. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study (published online ahead of print April 9, 2008). J Antimicrob Chemother 2008;62(1):172-176. doi:10.1093/jac/dknl57.
69. Haas DA, Pyrin BR, Sands TD. Drug use for the pregnant or lactating patient. Gen Dent 2000;48(1):54-60.
70. Hilgers KK, Douglass J, Mathieu GP. Adolescent pregnancy: a review of dental treatment guidelines. Pediatr Dent 2003;25(5): 459-467.
71. Cengiz SB. The pregnant patient: considerations for dental management and drug use. Quintessence Int 2007;38(3):el33-el42.
72. Suresh L, Radfar L. Pregnancy and lactation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97(6):672-682.
73. California Dental Association Foundation; American College of Obstetricians and Gynecologists, District DC. Oral health during pregnancy and early childhood: evidence-based guidelines for health professionals. J Calif Dent Assoc 2010;38(6):391-403,405-440.
74. Wilburn-Goo D, Lloyd LM. When patients become cyanotic: acquired methemoglobinemia. JADA 1999;130:826-831.
75. Fayans EP, Stuart HR, Carsten D, Ly Q, Kim H. Local anesthetic use in the pregnant and postpartum patient. Dent Clin North Am 2010;54(4):697-713.
76. Whited C, Cohen SM. Nasal teracaine spray-induced methemoglobinemia (published online ahead of print Sept. 7,2011). Otolaryngol Head Neck Surg 2012;146(4):678-679. doi:10.1177/ 0194599811421124.
77. Orr TM, Orr DL. Methemoglobinemia secondary to over-the-counter Anbesol (published online ahead of print Oct. 16,2010). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111(2):e7-e11. doi:10.10167j.tripleo.2010.06.011.
78. Annabi EH, Barker SJ. Severe methemoglobinema detected by pulse oximetry. Anesth Analg 2009;108(3);898-899.
79. Guay J. Methemoglobinemia related to local anesthetics: a summary of 242 episodes. Anesth Analg 2009;108(3):837-845.
80. Moore PJ, Braatvedt GD. Acquired methemoglobinaemia in pregnancy: a case report. S Afr Med J 1985;67(1):23-24.
81. Hood DD, Dewan DM, James FM 3rd. Maternal and fetal effects of epinephrine in gravid ewes. Anesthesiology 1986;64(5):610-613.
82. Rieken SE, Terezhalmy GT. The pregnant and breast-feeding patient. Quintessence Int 2006;37(6):455-468.
83. Porter RS, ed. The Merck Manual Home Health Handbook for Patients and Caregivers: Drug Use During Pregnancy, www.merckmanuals.com/home/womens-health- issues/drug-use-during-pregnancy/drug-use-during-pregnancy.html#v810071. Accessed June 8,2012.
84. Hale TW. Medications and Mother's Milk: A Manual of Lactational Pharmacology. 14th ed. AmaruTo, Texas: Hale Publishing; 2010:359-360.
85. Neves IL, Avila WS, Neves RS, et al. Maternal-fetal monitoring during dental procedure in patients with heart valve disease. Arq Bras Cardiol 2009;93(5):463-472.
86. Robertson VJ, Taylor SE, Gage TW. Quantitative and qualitative analysis of the pressor effects of levonordefrin. J Cardiovasc Pharmacol 1984;6(5):929-935.
87. Lawaty I, Drum M, Reader A, Nusstein J. A prospective, randomized, double-blind comparison of 2 percent mepivacaine with 1:20,000 levonordefrin versus 2 percent lidocaine with 1:100,000 epinephrine for maxillary infiltrations. Anesth Prog 2010;57(4):139-144.
88. Guglielmo A, Reader A, Nist R, Beck M, Weaver J. Anesthetic efficacy and heart rate effects of the supplemental intraosseous injection of 2 percent mepivacaine with 1:20,000 levonordefrin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87(3):284-293.
89. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002;53(1):39-49.
90. Jauniaux E, Jurkovic D, Lees C, Campbell S, Gulbis B. In-vivo study of diazepam transfer across the first trimester human placenta. Hum Reprod 1996;ll(4):889-892.
91. Howie WO, McMullen PC. Breastfeeding problems following anesthetic administration. J Perinat Educ 2006;15(3):50-57.
92. Donaldson M, Chanpong B, Gizzarelli G. Oral sedation: a primer on axuriolysis for the adult patient. Anesth Prog 2007;54(3): 118-129.
93. Wen SW, Yang T, Krewski D, et al. Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian population (published online ahead of print Feb. 21, 2008). J Perinatal 2008; 28(5):324-329.doi:10.10367jp. 2008.6.
94. Kalian B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy, part 3: congenital malformations in the infants (published online ahead of print Feb. 6, 2007). Eur J Clin Pharmacol 2007;63(4):383-388.doi:10. 1007/s00228-006-0259-z.
95. Wen SW, Demissie KW, Liu S. Adverse outcomes in pregnancies of asthmatic women: results from a Canadian population. Ann Epidemiol 2001;11(1):7-12.
96. Demissie K, Breckenridge MB, Rhoads GG. Infant and maternal outcomes in the pregnancies of asthmatic women. Am J Respir Crit Care Med 1998;158(4):1091-1095.
97. Lindberg C, Boreus LO, de Chateau P, Lindstrom B, Lonner-holm G, Nyberg L. Transfer of terbutaline into breast milk. Eur J Resp Dis 1984;134:87-91.
98. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol 1993;168(5): 1393-1399.
99. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter (published correction appears in J Allergy Clin Immunol 2008;122[1]:68)
100. J Allergy Clin Immunol 2005; 115(3 suppl 2):S483-S523.
101. Brown AF. Anaphylaxis gets the adrenaline going. Emerg Med J 2004;21(2):128-129.
102. McFadden ER Jr. Acute severe asthma. Am J Respir Crit Care Med 2003;168(7):740-759.
103. Radzyminski S. The effect of ultra low dose epidural analgesia on newborn breastfeeding behaviors. J Obstet Gynecol Neonatal Nurs 2O03;32(3):322-331.
104. Longnecker DE, Grazis PA, Eggers GW Jr. Naloxone for antagonism of morphine-induced respiratory depression. Anesth Analg 1973;52(3):447-453.
105. Klotz U, Kanto J. Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). Clin Pharmacokinet 1988;14(1):1-12.
106. Johnson MR, Andrews MA, Seckl JR, Lightman, SL. Effect of naloxone on neurohypophyseal peptide responses to breast feeding and breast stimulation in man. Clin Endocrinol 1990;33(1):81-86.
107. Cholst IN, Wardlaw SL, Newman CB, Frantz AG. Prolactin response to breast stimulation in lactating women is not mediated by endogenous opioids. Am J Obstet Gynecol 1984;150 (5 Pt 1):558-561.
108. Richard P, Autret E, Bardol J, et al. The use of flumazenil in a neonate. J Toxicol Clin Toxicol 1991;29(1):137-140.
109. Dixon JC, Speidel BD, Dixon JJ. Neonatal flumazenil therapy reverses maternal diazepam. Acta Paediatr 1998;87(2):225-226.
110. Sheikh AU, Harper MA. Myocardial infarction during pregnancy: management and outcome of two pregnancies. Am J Obstet Gynecol 1993;169(2 part 1):279-283.
111. Maekawa K, Ohnishi H, Hirase T, Yamada T, Matsuo T. Acute myocardial infarction during pregnancy caused by coronary artery spasm. J Intern Med 1994;235(5):489-492.